Nureca Intrinsic Value
NURECA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹319.44 | ₹255.55 - ₹383.33 | +13.0% | EPS: ₹14.52, Sector P/E: 22x |
| Book Value Method | asset | ₹388.00 | ₹349.20 - ₹426.80 | +37.2% | Book Value/Share: ₹194.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹320.00 | ₹288.00 - ₹352.00 | +13.2% | Revenue/Share: ₹160.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹240.00 | ₹216.00 - ₹264.00 | -15.1% | EBITDA: ₹24.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹113.12 | ₹90.50 - ₹135.74 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹92.93 | ₹83.64 - ₹102.22 | -67.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹224.33 | ₹201.90 - ₹246.76 | -20.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹160.00 | ₹144.00 - ₹176.00 | -43.4% | ROE: 8.2%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹251.75 | ₹226.58 - ₹276.93 | -11.0% | EPS: ₹14.52, BVPS: ₹194.00 |
Want to compare with current market value? Check NURECA share price latest .
Valuation Comparison Chart
NURECA Intrinsic Value Analysis
What is the intrinsic value of NURECA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Nureca (NURECA) is ₹240.00 (median value). With the current market price of ₹282.80, this represents a -15.1% variance from our estimated fair value.
The valuation range spans from ₹92.93 to ₹388.00, indicating ₹92.93 - ₹388.00.
Is NURECA undervalued or overvalued?
Based on our multi-method analysis, Nureca (NURECA) appears to be trading above median value by approximately 15.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 63.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.08 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 8.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.76x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Nureca
Additional stock information and data for NURECA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-19 Cr | ₹-19 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹10 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹35 Cr | ₹-20 Cr | Positive Operating Cash Flow | 6/10 |